InflaRx N.V. (IFRX)
About InflaRx N.V.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $271.0M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $271.0M
- Shares outstanding
- 155.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 8, 2017
InflaRx N.V. (IFRX) Stock Price
- Trading 36% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review InflaRx N.V..
Write a review
News about InflaRx N.V.
News & sentiment via Polygon.io
InflaRx N.V.: frequently asked questions
Is InflaRx N.V. an American company?
InflaRx N.V. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is InflaRx N.V. publicly traded?
Yes — InflaRx N.V. is a publicly traded company. Its stock trades under the ticker symbol IFRX on the NASDAQ.
What does InflaRx N.V. do?
InflaRx N.V. is an American Pharmaceuticals company in the Health & Beauty sector.
